Abstract
Based upon the clinical presentation of chronic fatigue syndrome (CFS), we hypothesized that proinflammatory cytokines may play a role in the pathogenesis of the disease. We therefore undertook a retrospective cross-sectional study to examine the role of TNF-α in patients with CFS. Our results suggest a significant increase serum TNF-α in patients with CFS (P < 0.0001) compared to non-CFS controls. This study supports the further examination of the role of proinflammatory mediators in CFS. Furthermore, the clinical testing of TNF-α blockers and other antiinflammatory agents for the treatment of this disease is warranted.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Visser J, Blauw B, Hinloopen B, Brommer E, de Kloet ER, Kluft C, Nagelkerken L: CD4 T lymphocytes from patients with chronic fatigue syndrome have decreased interferon-gamma production and increased sensitivity to dexamethasone. J Infect Dis 177(2):451–454, 1998
Cannon JG, Angel JB, Abad LW, Vannier E, Mileno MD, Fagioli L, Wolff SM, Komaroff AL: Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome. J Clin Immunol 17(3):253–261, 1997
Bennett AL, Chao CC, Hu S, Buchwald D, Fagioli LR, Schur PH, Peterson PK, Komaroff AL: Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J Clin Immunol 17(2):160–166, 1997
Buchwald D, Wener MH, Pearlman T, Kith P: Markers of inflammation and immune activation in chronic fatigue and chronic fatigue syndrome. J Rheumatol 24(2):372–376, 1997
Levy JA: Viral studies of chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S117-S120, 1994
Krakauer T, Vilcek J, Oppenheim JJ: Proinflammatory cytokines: TNF and IL-1 families, chemokines, TGF-β, and others. In Fundamental Immunology, 4th ed, WE Paul (ed). New York, Lippincott-Raven, 1999, pp 775–811
Feldmann M, Brennan FM, Maini R: Cytokines in autoimmune disorders. Int Rev Immunol 17(1–4):217–228, 1998
Gupta S, Aggarwal S, See D, Starr A: Cytokine production by adherent and nonadherent mononuclear cells in chronic fatigue syndrome. J Psychiatr Res 31(1):149–156, 1997
Suhadolnik RJ, Reichenbach NL, Hitzges P, Sobol RW, Peterson DL, Henry B, Ablashi DV, Muller WE, Schroder HC, Carter WA, et al.: Upregulation of the 2–5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S96-S104, 1994
Strayer DR, Carter WA, Brodsky I, Cheney P, Peterson D, Salvato P, Thompson C, Loveless M, Shapiro DE, Elsasser W, et al.: A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome. Clin Infect Dis 18(Suppl 1):S88-S95, 1994
Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 28;304(4):253–259, 1999
Bauditz J, Lochs H, Schreiber S: Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 29;338(5):334, 1998
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moss, R.B., Mercandetti, A. & Vojdani, A. TNF-α and Chronic Fatigue Syndrome. J Clin Immunol 19, 314–316 (1999). https://doi.org/10.1023/A:1020595709352
Issue Date:
DOI: https://doi.org/10.1023/A:1020595709352